MXPA94000108A - Transdermal hormone replacement therapy. - Google Patents

Transdermal hormone replacement therapy.

Info

Publication number
MXPA94000108A
MXPA94000108A MXPA94000108A MX9400108A MXPA94000108A MX PA94000108 A MXPA94000108 A MX PA94000108A MX PA94000108 A MXPA94000108 A MX PA94000108A MX 9400108 A MX9400108 A MX 9400108A MX PA94000108 A MXPA94000108 A MX PA94000108A
Authority
MX
Mexico
Prior art keywords
progestin
substance
transdermal
estrogen
dominant activity
Prior art date
Application number
MXPA94000108A
Other languages
Spanish (es)
Inventor
F Casper Robert
Original Assignee
Jencap Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jencap Res Ltd filed Critical Jencap Res Ltd
Publication of MXPA94000108A publication Critical patent/MXPA94000108A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female a series of alternating phases of from about one to about four days of estrogen dominant activity and phases of from about one to about four days of progestin dominant activity, with the estrogen dominant activity phase consisting of administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance and the progestin dominant activity phase consisting of administering a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
MXPA94000108A 1992-12-28 1994-01-03 Transdermal hormone replacement therapy. MXPA94000108A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99682092A 1992-12-28 1992-12-28

Publications (1)

Publication Number Publication Date
MXPA94000108A true MXPA94000108A (en) 2004-08-20

Family

ID=25543344

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA94000108A MXPA94000108A (en) 1992-12-28 1994-01-03 Transdermal hormone replacement therapy.

Country Status (8)

Country Link
EP (1) EP0675720A1 (en)
CN (1) CN1097987A (en)
CA (1) CA2152780A1 (en)
IL (1) IL108183A0 (en)
MX (1) MXPA94000108A (en)
SI (1) SI9300687A (en)
WO (1) WO1994014450A1 (en)
ZA (1) ZA939686B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101601B (en) * 1987-09-24 1998-07-31 Jencap Res Ltd The contraceptive and the use of estrogen and progestin in the method of making the contraceptive
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method

Also Published As

Publication number Publication date
SI9300687A (en) 1994-09-30
ZA939686B (en) 1994-08-29
WO1994014450A1 (en) 1994-07-07
CN1097987A (en) 1995-02-01
IL108183A0 (en) 1994-04-12
CA2152780A1 (en) 1994-07-07
EP0675720A1 (en) 1995-10-11

Similar Documents

Publication Publication Date Title
GEP20002146B (en) Therapeutic Peptide Derivatives
ATE304845T1 (en) SKIN PATCH CONTAINING TESTOSTERONE AND, IF APPROPRIATE, ESTROGEN
HUT71224A (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
HU9600592D0 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
GEP20063773B (en) Steroid Sulphatase Inhibitors
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
UA32429C2 (en) Agent for treatment of patient with enuresis
IL111293A0 (en) Pharmaceutical compositions comprising 5 alpha-reductase type 2 inhibitor for treating androgenic alopecia
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
MXPA94000108A (en) Transdermal hormone replacement therapy.
AR003979A1 (en) TRANSDERMIC ADMINISTRATION OF VOROZOL.
ATE149840T1 (en) TREATMENT OF LIVER CANCER
WO1995007708A3 (en) Therapeutic use of the retinoblastoma susceptibility gene product
PT1007085E (en) USES OF GROWTH HORMONE IN COMPOSITIONS FOR THE TREATMENT OF INSULIN RESISTANCE IN THE HEART
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
DE69331237D1 (en) ANTIATHEROSCLEROTIC AGENTS
UA15068A (en) Method for medical rehabilitation of patients with the dystrophic diseases of musculoskeletal system
MX9603833A (en) Improved cancer treatment with temozolomide.
Stenbjerg F VIII Inhibitors Treated with Low-Dose F VIII
UA7955A (en) Method for treating pulmonary tuberculosis
UA12628A (en) Method for treating acute viral hepatitis
UA10000A (en) Method for treating acute insufficiency of tissue respiration